Results 51 to 60 of about 3,406 (148)

Tenecteplase: biochemical and clot lysis activity comparisons

Frontiers in Pharmacology
IntroductionIn the last decades, the recombinant tissue plasminogen activator alteplase has been the standard fibrinolytic treatment of acute myocardial infarction, pulmonary embolism, and acute ischemic stroke.
Jan Bechmann, Ira Schmid, Simone Brand, Felix Miller, Chengzhi Zhang   +4 more
doaj   +1 more source

Alteplase- and Tenecteplase-Related Errors and Risk Mitigation Strategies in the Treatment of Acute Ischemic Stroke: A Study of Event Reports From 52 Hospitals

Patient Safety
# Background Alteplase and tenecteplase are thrombolytic agents used to treat patients with acute ischemic stroke (AIS). Despite the convenient bolus dosing of tenecteplase, its off-label use for AIS creates new patient safety challenges that are ...
Myungsun Ro, Matthew A. Taylor, Rebecca Jones   +2 more
doaj   +1 more source

A Systematic Review of the Efficacy and Safety of Tenecteplase Versus Alteplase in Acute Ischemic Stroke: A Time to Pass the Torch

Stroke: Vascular and Interventional Neurology
Alteplase, a biosynthetic form of human tissue‐type plasminogen activator, is Food and Drug Administration‐approved for the treatment of acute ischemic stroke and currently the standard of care for thrombolytic therapy.
Miguel Rodriguez, Christian Sidebottom, Drew A. Wells, Thirumalaivasan Dhasakeerthi, Lisa Hayes, Cheran Elangovan, Balaji Krishnaiah   +6 more
doaj   +1 more source

Intravenous tenecteplase compared with alteplase for minor ischaemic stroke: a secondary analysis of the AcT randomised clinical trial

Stroke and Vascular Neurology
Background In ischaemic stroke, minor deficits (National Institutes of Health Stroke Scale (NIHSS) ≤5) at presentation are common but often progress, leaving patients with significant disability.
Dar Dowlatshahi, Mohammed A Almekhlafi, Tolulope Sajobi, Aleksandra Pikula, Ashfaq Shuaib, Alexandre Y Poppe, Richard H Swartz, Fouzi Bala, Ibrahim Alhabli, Aleksander Tkach, Heather Williams, Shelagh B Coutts, Nishita Singh, Anurag Trivedi, Andrew Demchuk, Gary Hunter, Brian H Buck, Faysal Benali, Bijoy Menon, MacKenzie Horn, Radhika Nair, Thalia Field, Mahesh Kate, Negar Asdaghi, Robert Sarmiento, Ayoola Ademola, Houman Khosravani, Herbert Alejandro Manosalva Alzate, Luciana Catanese   +28 more
doaj   +1 more source

Tenecteplase versus alteplase in elderly stroke: a post hoc analysis of the AcT trial

Stroke and Vascular Neurology
Background Stroke rates rise steeply with age but data on tenecteplase in patients ≥80 years remain limited. This post-hoc analysis of the AcT trial compared tenecteplase with alteplase in this population.Methods The analysis included all Alteplase ...
Mohammed A Almekhlafi, Tolulope Sajobi, Richard H Swartz, Aleksander Tkach, Brian Buck, Nishita Singh, Bijoy Menon, Luciana Catanese, Taha Aslan, Mohamed AlShamrani   +9 more
doaj   +1 more source

Efficacy and Safety of Intravenous Tenecteplase Before Endovascular Thrombectomy for Acute Ischemic Stroke: The Multicenter, Randomized, BRIDGE‐TNK Trial Protocol

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Six randomized trials have not detected a difference between intravenous alteplase plus endovascular thrombectomy and endovascular thrombectomy alone in stroke.
Zhongming Qiu, Fengli Li, Dongjing Xie, Guangxiong Yuan, Thanh N. Nguyen, Kai Zhou, Raul G. Nogueira, Jeffrey L. Saver, Bruce C.V. Campbell, Gregory W. Albers, Hongfei Sang, Linyu Li, Yan Tian, Zhaoyou Meng, Duolao Wang, Wenjie Zi, Qingwu Yang   +16 more
doaj   +1 more source

Ethnic Differences in the Safety and Efficacy of Tenecteplase Versus Alteplase for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis [PDF]

Journal of Stroke
Background and Purpose Tenecteplase is a thrombolytic agent with pharmacological advantages over alteplase and has been shown to be noninferior to alteplase for acute ischemic stroke in randomized trials.
Jin Hean Koh, Claire Yi Jia Lim, Lucas Tze Peng Tan, Ching-Hui Sia, Kian Keong Poh, Vijay Kumar Sharma, Leonard Leong Litt Yeo, Andrew Fu Wah Ho, Teddy Wu, William Kok-Fai Kong, Benjamin Yong Qiang Tan   +10 more
doaj   +1 more source

Risk of angioedema and thrombolytic therapy among stroke patients: An analysis of data from the FDA Adverse Event Reporting System database

Neurotherapeutics
The angioedema risk may vary among stroke patients receiving different thrombolytic agents. This study aimed to investigate the angioedema risk associated with different thrombolytic agents and to identify associated risk factors.
Hunong Xiang, Yu Ma, Xiaochao Luo, Jian Guo, Minghong Yao, Yanmei Liu, Ke Deng, Xin Sun, Ling Li   +8 more
doaj   +1 more source

Spinal subdural hematoma as a complication of tenecteplase treatment for acute ischemic stroke: A case report

Heliyon
Intravenous thrombolysis is an effective treatment for acute ischemic stroke. The ESO recommends that tenecteplase be used for thrombolytic therapy in stroke within 4.5h of onset.
Sisi Zhao, Lingtao Tang, Yanpeng Lu, Yingyi Li   +3 more
doaj   +1 more source

Real-world data of tenecteplase vs. alteplase in the treatment of acute ischemic stroke: a single-center analysis

Frontiers in Neurology
BackgroundThis retrospective observational cohort study aimed to evaluate whether tenecteplase’s use for acute ischemic stroke (AIS) has time management advantages and clinical benefits.Methods144 AIS patients treated with alteplase and 120 with ...
Yu Yao, Yuefei Wu, Xiaoqin Zhang, Chang Liu, Lingling Cai, Yisha Ying, Jianhong Yang   +6 more
doaj   +1 more source